ARINA-1—Nebulized Treatment for Bronchiectasis

Many people have been asking about ARINA-1, a promising proprietary nebulized solution in development for bronchiectasis.

To get the latest, I reached out to Dan Copeland, CEO of Renovion, Inc., the company leading this innovative work.

What is ARINA-1?

ARINA-1 is an investigational, at-home nebulized therapy designed to:

• Thin mucus to improve airway clearance
  
  
• Reduce airway inflammation without the side effects of steroids
  
  
• Inhibit harmful bacteria, including those linked to recurrent infections


• In 2024, Renovion completed a randomized, phase 2, double-blind, placebo-controlled study evaluating the safety and efficacy of ARINA-1 in people with non-cystic fibrosis bronchiectasis (NCFBE).

Clinical Trials

Early clinical results suggest ARINA-1 begins working within days and delivers promising outcomes. If approved, it could become the first non-antibiotic nebulized therapy specifically for bronchiectasis—addressing a critical unmet need for patients.

An Update from Dan Copeland

“Renovion is currently in discussions with the FDA about the importance of treating bronchiectasis symptoms early—before they progress into exacerbations.
The company is preparing for a Phase 3 clinical trial, focusing on individuals with mild to moderate NCFBE. The goal: to offer a first-line therapy that effectively manages daily symptoms and helps slow disease progression.”

I’ll continue to follow ARINA-1’s development and share updates as more information becomes available.